PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS).
PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.


Biotechnology

Clinical Trials

Life Sciences

Therapeutics

PolTREG S.A.

Piotr Trzonkowski

Karol Ptach

Dan Shelly

This department focuses on the research and development of biotechnological solutions and innovations.

Biotechnology Research

This department oversees organizational governance and strategic direction.

Supervisory Board

This department oversees the planning, execution, and completion of projects to ensure they meet their objectives and timelines.

Project Management

This department oversees the strategic growth initiatives and operational efficiencies within the business development function.

Business Development Operations

This department ensures product quality and adherence to standards through testing and inspection processes.

Quality Assurance

This department is responsible for coordinating technical and maintenance activities to ensure efficient operational processes.

PolTREG S.A.

Org chart

Teams

Biotechnology Research

Supervisory Board

Project Management

Business Development Operations

Quality Assurance

Technical Operations

Offices

PolTREG S.A.

Org chart

Teams

Biotechnology Research

Supervisory Board

Project Management

Business Development Operations

Quality Assurance

Technical Operations

Offices

Related companies